Coherus Oncology, Inc. (CHRS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.16. The rating moved from Strong Oversold to Oversold on October 1, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$1.16
• Last changeMoved from Strong Oversold to Oversold on October 1, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

The broader market is in a risk-off mode with reduced tolerance for small-cap biotech financing, and healthcare policy/payer pressures add an extra headwind to pricing and access. Potential upside remains binary — a positive trial or strategic partnership could materially improve the outlook — but near-term dilution, competitive pressures, and reimbursement uncertainty make downside more likely before such catalysts emerge.

Key factors

• Limited commercial revenue base and likely negative free cash flow, increasing dependence on external financing
• Binary pipeline risk: valuation tied to clinical readouts or partner deals that could be binary catalysts
• Risk-off market tone and healthcare IPO/financing window cooling, reducing appetite for small-cap oncology capital raises
• Policy and payer pressure (Medicare negotiation) that can compress pricing and access for specialty therapies
• Narrow market position with competing larger biopharma players able to exert pricing and distribution advantages

Risks

• Near-term dilution from equity raises if cash runway is short
• Clinical trial delays, negative readouts, or regulatory setbacks that materially reduce asset value
• Reimbursement and pricing pressure from Medicare negotiation and aggressive payer contracting
• Competition from larger oncology and biologics players with deeper commercialization resources
• Low liquidity and heightened volatility in the stock, increasing downside on market-stress events
• Geopolitical or macro shocks that further depress small-cap biotech flows and M&A appetite

Latest MarketMoodz coverage

• Applied Materials Leads Premarket Rally as Chip Equipment Soars2026-02-13

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.